A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies

International Journal of Molecular Sciences

Munmun Rahman²  Kentaro Nakayama²  Tomoka Ishibashi²  Masako Ishikawa²  Mohammed Tanjimur Rahman²  Hiroshi Katagiri²  Atsuko Katagiri²  Kouji Iida²  Yoshihiro Kikuchi¹ 

[1] Department of Gynecology, Ohki Memorial Kikuchi Cancer Clinic for Women, Tokorozawa, Saitama 3591133, Japan; E-Mail:;Department of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo, Shimane 6938501, Japan; E-Mails:

关键词: ovarian clear cell carcinoma;    biomarkers;    PIK3CA;    mTOR inhibitor;   

DOI  :  10.3390/ijms14036067

来源: mdpi

【 摘 要 】

Ovarian cancer treatment presently does not reflect molecular differences in histologic subtype. Ovarian clear cell carcinoma (OCCC) exhibits several differences in terms of molecular pathogenesis and tumor behavior from the more common, chemosensitive, serous carcinomas, which makes OCCC a candidate for targeted therapies. A 53-year-old Japanese woman was diagnosed with stage IIIc ovarian clear cell adenocarcinoma with marked chemoresistance to conventional regimens. She demonstrated a partial response to a multikinase inhibitor. The tumor was resistant to PI3K/mTOR pathway inhibitors despite harboring a PIK3CA mutation. The present case suggests a role for targeted therapies in the treatment of OCCC and a need for the identification of biomarkers that will predict response to targeted therapies.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland.